Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 13:2022:7827821.
doi: 10.1155/2022/7827821. eCollection 2022.

Association of Statin Use with the Risk of Incident Prostate Cancer: A Meta-Analysis and Systematic Review

Meng-Yao Xu  1 , Ye An  1 , Chen-Qian Liu  1 , Jin-Zhou Xu  1 , Xing-Yu Zhong  1 , Na Zeng  1 , Jian-Xuan Sun  1 , Qi-Dong Xia  1 , Shao-Gang Wang  1
Affiliations

Association of Statin Use with the Risk of Incident Prostate Cancer: A Meta-Analysis and Systematic Review

Meng-Yao Xu et al. J Oncol. .

Abstract

Background: With the growth and aging of population, the incidence of prostate cancer will increase year by year, which is bound to bring greater economic burden to the society. There has been greater interest in the anticancer effects of statin in recent years. It is controversial whether statin use is associated with the risk of prostate cancer (PCa). Thus, we conducted a meta-analysis and systematic review to explore the effects of statin use and their duration and cumulative dose on the overall incidence of PCa.

Method: The study was conducted according to the latest guidelines for PRISMA 2020. We searched PubMed and other databases for studies about the association of statin use with the risk of incident prostate cancer between January 1, 1990, and April 11, 2022. Two independent researchers extracted data and evaluated the quality of the studies. R x64 4.1.2 and random-effects model were used for data statistics. Relative risk (RR) and odds ratio (OR) effective values with a 95% confidence interval (95% CI) were used to assess the main results.

Results: The results of 6 RCT and 26 cohort studies showed that statins did not significantly associate with the incidence of PCa (RR = 0.94, 95% CI: 0.82-1.08). The similar results were obtained from 9 case-control studies (OR = 1.03, 95% CI: 0.99-1.07). However, statins were associated with a lower risk of Pca (RR = 0.44, 95% CI: 0.28-0.70) when the cumulative defined daily dose (cDDD) was high. Using statins for more than five years could be associated with a reduced incidence of Pca (RR = 0.47, 95% CI: 0.23-0.97). There was a significant heterogeneity in these studies (RCT and cohort study: I 2 = 98%, P < 0.01; case-control study: I 2 = 72%, P < 0.01).

Conclusion: We concluded that statins had a neutral association with the overall risk of PCa. High cDDD and long duration were associated with a lower risk of PCa.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA (preferred reporting items for systematic reviews and meta-analyses) flow chart of studies selection.
Figure 2
Figure 2
The effect of statin usage on the risk of incident prostate cancer using the random-effects model. (a) The forest plot for the RR. (b) The forest plot for the OR.
Figure 3
Figure 3
Forest plot of RR for subgroup analysis based on study design, country and statin type.
Figure 4
Figure 4
The meta-regression for risk of PCa and race (the percentage of white).
Figure 5
Figure 5
Forest plot of RR for the effect of (a) high cDDD and (b) long duration of statins on PCa.
Figure 6
Figure 6
The forest plot for sensitivity analysis. (a) The forest plot for the RR. (b) The forest plot for the OR.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Culp M. B., Soerjomataram I., Efstathiou J. A., Bray F., Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. European Urology . 2020;77(1):38–52. doi: 10.1016/j.eururo.2019.08.005. - DOI - PubMed
    1. Torre L. A., Bray F., Siegel R. L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians . 2015;65(2):87–108. doi: 10.3322/caac.21262. - DOI - PubMed
    1. He H., Liang L., Han D., Xu F., Lyu J. Different trends in the incidence and mortality rates of prostate cancer between China and the USA: a joinpoint and age-period-cohort analysis. Frontiers of Medicine . 2022;9 doi: 10.3389/fmed.2022.824464.824464 - DOI - PMC - PubMed
    1. Iannelli F., Lombardi R., Milone M. R., et al. Targeting mevalonate pathway in cancer treatment: repurposing of statins. Recent Patents on Anti-Cancer Drug Discovery . 2018;13(2):184–200. doi: 10.2174/1574892812666171129141211. - DOI - PubMed
    1. Rice K. R., Koch M. O., Cheng L., Masterson T. A. Dyslipidemia, statins and prostate cancer. Expert Review of Anticancer Therapy . 2012;12(7):981–990. doi: 10.1586/era.12.75. - DOI - PubMed

LinkOut - more resources